Enliven Therapeutics, Inc. (ELVN) Quarterly Cash Flow Statement

120+ quarters historyFree accessUpdated daily

Enliven Therapeutics, Inc. (ELVN) quarterly cash flow statement — complete operating, investing & financing history

Quarterly statement

ELVN Cash Flow Statement

Enliven Therapeutics, Inc. (ELVN) cash flow statement — 9-year operating, investing & financing cash flows

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23	Q2'23	Q1'23	Q4'22	Q3'22	Q2'22	Q1'22	Q4'21

Cash from Operations	-12.55M	-18.53M	-19.29M	-15.84M	-13.28M	-17.06M	-24.13M	-17.2M	-12.19M	-20.43M	-23.36M	-12.48M	-15.89M	-12.05M	-20.84M	-8.14M	-6.45M	-7.12M	-10.36M	-12.48M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	5.45%	-8.64%	20.04%	7.93%	-8.91%	16.53%	-3.28%	-37.82%	23.29%	-69.6%	-12.08%	-53.25%	-146.53%	-69.13%	-101.18%	34.76%	40.86%	31.27%	20.42%	-50.99%
Net Income	-27.7M	-32.48M	-23.63M	-29.67M	-20.15M	-25.34M	-28.54M	-23.18M	-23.16M	-19.95M	-22.74M	-19.37M	-20.77M	-16.72M	-14.72M	-9.55M	-10.55M	-8.89M	-8.67M	-14.32M
Depreciation & Amortization	13K	7K	14K	46K	62K	81K	74K	80K	80K	78K	79K	77K	78K	74K	67K	64K	60K	52K	39K	25K
Stock-Based Compensation	8.06M	13.91M	7.4M	12.31M	7.18M	7.72M	6.8M	5.34M	5.18M	5.14M	4.51M	3.06M	3.4M	4.2M	2.26M	735K	1.1M	701K	654K	0
Deferred Taxes	0	0	0	0	0	0	0	0	0	0	0	-4.17M	0	0	0	0	0	0	0	0
Other Non-Cash Items	-870K	637K	359K	253K	-221K	160K	40K	1.07M	719K	-1.32M	-582K	2.46M	-1.76M	-831K	0	0	1.74M	0	0	1.03M
Working Capital Changes	7.95M	-605K	-3.43M	1.22M	-157K	313K	-2.5M	-510K	4.99M	-4.38M	-4.63M	5.46M	3.15M	1.23M	-8.45M	606K	1.21M	1.01M	-2.38M	779K
Change in Receivables	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change in Payables	2.59M	-1.5M	-519K	828K	-1.02M	789K	220K	323K	-64K	-1.6M	2.15M	-961K	-1.59M	-188K	492K	18K	1.36M	592K	-1.56M	-116K
Cash from Investing	26.33M	-441.57M	42.53M	12.38M	-4.06M	-183.59M	1.43M	727K	14.83M	-33.66M	-17.89M	38.69M	-35.55M	-151.52M	-31K	-101K	-14K	-303K	-194K	-14.49M
Capital Expenditures	-94K	-99K	0	0	1K	-139K	-20K	0	-22K	-2K	-20K	-14K	-16K	-88K	-31K	-101K	-14K	-303K	-194K	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Acquisitions	0	0	0	0	0	0	0	0	0	0	0	0	-40M	0	0	0	0	0	0	0
Investments	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	213K	0	0	0	0	52.4M	10M	0	0	40M	0	0	0	0	0	0	0
Cash from Financing	2.39M	463.42M	10.05M	623K	-368K	218.38M	234K	39.97M	1.12M	1.81M	90.27M	90K	-425K	-2.82M	237.44M	-2.38M	164K	5K	409K	-10K
Debt Issued (Net)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Equity Issued (Net)	2.39M	463.06M	10.05M	623K	-368K	218.38M	234K	-50.51M	1.12M	1.81M	90M	90K	-425K	-1.5M	163.04M	0	164K	5K	409K	-10K
Dividends Paid	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Share Repurchases	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Financing	0	354K	0	0	0	0	0	90.48M	0	0	270K	0	0	-1.32M	74.4M	-2.38M	0	0	0	0
Net Change in Cash	16.16M	3.32M	33.29M	-2.84M	-17.7M	17.73M	-22.47M	23.5M	3.75M	-52.29M	49.02M	26.35M	-51.87M	-166.39M	203.9M	-10.62M	19.06M	-6.05M	-11.82M	-26.99M
Free Cash Flow	-12.65M	-18.63M	-19.29M	-15.84M	-13.28M	-17.2M	-24.15M	-17.2M	-12.21M	-20.44M	-23.38M	-12.5M	-15.91M	-12.14M	-20.88M	-8.25M	-6.46M	-7.43M	-10.55M	-12.48M
FCF Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
FCF Growth %	4.74%	-8.34%	20.11%	7.93%	-8.7%	15.86%	-3.28%	-37.67%	23.22%	-68.39%	-12%	-51.54%	-146.25%	-63.42%	-97.77%	33.95%	40.73%	28.35%	19.01%	-51.06%
FCF per Share	-0.16	-0.28	-0.31	-0.28	-0.21	-0.33	-0.48	-0.35	-0.25	-0.43	-0.56	-0.30	-0.39	-0.30	-1.13	-1.25	-0.98	-1.13	-1.61	-1.90
FCF Conversion (FCF/Net Income)	0.45x	0.57x	0.82x	0.53x	0.66x	0.67x	0.85x	0.74x	0.53x	1.02x	1.03x	0.64x	0.77x	0.72x	1.42x	0.85x	0.61x	0.80x	1.20x	1.49x
Interest Paid	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0